Financial Data and Key Metrics Changes - In Q4 2024, operational sales grew 23% and organic sales grew 20%, exceeding the guidance range of 14% to 16% [10] - Full year 2024 operational sales grew 18.5% while organic sales grew 16%, surpassing the guidance of approximately 15% [10] - Q4 adjusted EPS was $0.70, a 26% increase, exceeding the guidance range of $0.64 to $0.66 [11] - Full year adjusted EPS was $2.51, a 22% increase, exceeding the guidance range of $2.40 to $2.47 [11] - Adjusted operating margin for full year 2024 was 27%, an increase of 70 basis points [12] Business Line Data and Key Metrics Changes - Urology grew 8% in Q4 and 9% for the full year, with operational growth of 20% in Q4 [17] - Endoscopy sales grew 8% operationally and 7% organically in Q4, with full year growth of 9% operationally [20] - Cardiology sales grew 32% in Q4 and 25% for the full year, with interventional cardiology therapies growing 10% in Q4 [23] - Electrophysiology sales grew 172% in Q4 and 139% for the full year, driven by FerraPulse [29] Market Data and Key Metrics Changes - U.S. operational growth was 31% in Q4 and 21% for the full year [14] - Asia Pacific grew 12% operationally in Q4 and 16% for the full year, with strong performance in Japan and China [15] - Middle East, Europe, and Africa grew 12% in Q4 and 14% for the full year [14] Company Strategy and Development Direction - The company aims to continue outpacing market growth in 2025, with expectations of organic growth of 14% to 16% [12] - Focus on innovation and execution across global business units, with significant investments in product development [10] - Strategic acquisitions, such as Bolt Medical and Intera Oncology, are expected to enhance the product portfolio [12][24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in maintaining strong growth momentum despite potential competition in the PFA market [75] - Anticipated challenges in China due to VBP pricing pressures, but still expect mid-teens growth [17] - Management remains focused on driving differentiated results and enhancing the company culture [36] Other Important Information - Free cash flow for Q4 was $1.181 billion, with full year free cash flow of $2.648 billion, achieving 71% conversion [43] - The company has a cash reserve of $414 million and a gross debt leverage ratio of 2.2 times [44] - Guidance for 2025 includes reported revenue growth of 12.5% to 14.5% and organic growth of 10% to 12% [45] Q&A Session Summary Question: Thoughts on PFA and Watchmen growth - Management noted excellent momentum in both FerraPulse and Watchmen, with a slight uptick in Watchmen growth due to reimbursement changes [60] Question: Long-term growth expectations - Management indicated a goal to outgrow market growth rates and maintain double-digit EPS growth despite potential tax rate increases [68] Question: Risks and upside in guidance - Management acknowledged potential competition in the PFA market but emphasized strong momentum across various regions and product lines [75] Question: Margin management and cash flow - Management discussed strategies for operating margin expansion and maintaining a focus on high-quality M&A as a primary use of cash [85] Question: Update on TAVR franchise - Management stated that discussions regarding the U.S. TAVR franchise are ongoing, with strong performance in Europe despite some impacts from U.S. trials [123] Question: Mapping strategy and market share - Management confirmed an open platform strategy for mapping, with a focus on enhancing the OPAL platform while supporting competitive systems [126]

Boston Scientific Corporation (BSX) posted fourth-quarter 2024 adjusted earnings per share (EPS) of 70 cents, up 27.3% from the year-ago figure. The figure beat the Zacks Consensus Estimate by 7.7% and also exceeded the company’s adjusted earnings per share guidance range of 64-66 cents per share.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.The quarter’s adjustments included certain amortization expenses, acquisition/divestitures-related net charges, and restructuring and restructu ...

Boston Scientific (BSX) came out with quarterly earnings of $0.70 per share, beating the Zacks Consensus Estimate of $0.65 per share. This compares to earnings of $0.55 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 7.69%. A quarter ago, it was expected that this medical device manufacturer would post earnings of $0.58 per share when it actually produced earnings of $0.63, delivering a surprise of 8.62%.Over the last four qua ...

FOR IMMEDIATE RELEASE Boston Scientific announces results for fourth quarter and full year 2024 For the full year 2024, the company generated net sales of $16.747 billion, growing 17.6 percent on a reported basis, 18.5 percent on an operational basis and 16.4 percent on an organic basis. The company reported GAAP net income attributable to Boston Scientific common stockholders of $1.853 billion or $1.25 per share, compared to $1.570 billion or $1.07 per share a year ago, and delivered full year adjusted EPS ...

Core Insights - Boston Scientific Corporation reported net sales of $4.561 billion in Q4 2024, representing a growth of 22.4% on a reported basis, 23.1% operationally, and 19.5% organically compared to the previous year [1][9] - For the full year 2024, the company achieved net sales of $16.747 billion, an increase of 17.6% reported, 18.5% operationally, and 16.4% organically [2][12] - The company’s GAAP net income for Q4 2024 was $566 million or $0.38 per share, up from $504 million or $0.34 per share a year earlier, with adjusted EPS of $0.70 compared to $0.55 [1][9] - The CEO highlighted 2024 as one of the best years in the company's history, driven by an innovative portfolio and significant clinical achievements [3] Financial Performance - Q4 2024 net sales by segment included: MedSurg (12.4% reported), Cardiovascular (28.8% reported), and Urology (19.5% reported) [9][10] - Regional performance in Q4 2024 showed the U.S. with a 30.7% increase, EMEA at 10.8%, APAC at 11.1%, and LACA at 4.6% [9][10] - For the full year 2024, the U.S. contributed $10.210 billion in sales, a 21.2% increase, while EMEA and APAC saw increases of 13.0% and 11.9% respectively [12][12] Recent Developments - The company presented positive clinical trial findings for the WATCHMAN FLX™ device and the FARAPULSE™ system, indicating advancements in treatment efficacy [9][10] - Boston Scientific received FDA approval for new products, including the Vercise™ Cartesia™ leads and AGENT™ Drug-Coated Balloon, enhancing its product offerings [9][10] - The company completed acquisitions of Axonics, Inc. and Cortex, Inc., expanding its capabilities in medical technology [9][10] Guidance - For 2025, Boston Scientific estimates net sales growth of approximately 12.5% to 14.5% on a reported basis and 10% to 12% organically [14][15] - The company projects GAAP EPS for 2025 to be in the range of $1.86 to $1.93, with adjusted EPS expected between $2.80 and $2.87 [14][16]

The upcoming report from Boston Scientific (BSX) is expected to reveal quarterly earnings of $0.65 per share, indicating an increase of 18.2% compared to the year-ago period. Analysts forecast revenues of $4.4 billion, representing an increase of 18.1% year over year.Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.Prior to a company's ...

Core Insights - DeepSeek, a Chinese AI company, is becoming a significant player in the AI landscape with its cost-efficient large language models (LLMs) [1] - DeepSeek's models are designed to be significantly cheaper to train and deploy compared to U.S. models, potentially disrupting various industries reliant on AI [2][4] - The efficiency of DeepSeek's models allows for wider adoption, especially in regions with limited computational infrastructure [3] Industry Impact - The rise of DeepSeek has already impacted the U.S. stock market, with a loss of nearly $1 trillion following the news [9] - Companies like NVIDIA may face long-term repercussions as DeepSeek's models require less computational power, potentially reducing demand for high-end GPUs [9][10] - Cloud computing providers such as Microsoft and Amazon Web Services might experience pricing pressures due to the shift towards cheaper AI solutions [10] MedTech Sector - DeepSeek's cost-effective AI models could revolutionize the MedTech industry by making AI-driven diagnostics more affordable, enabling wider access to imaging analysis and early disease identification [11][12] - The affordability of DeepSeek's models may allow smaller hospitals and clinics to leverage advanced diagnostic tools, improving healthcare equity [12] - MedTech companies must evaluate how to leverage DeepSeek's innovations to remain competitive in the evolving landscape [13] Company-Specific Developments - Boston Scientific (BSX) is integrating AI across its operations and could benefit from DeepSeek's lower-cost models to enhance its medical devices and diagnostics [16][17] - Stryker (SYK) aims to enhance its healthcare solutions with AI and could further benefit from DeepSeek's cost-effective models for customization and innovation [19][20] - Tempus AI (TEM) leverages AI for precision medicine and could also benefit from integrating DeepSeek's models for advanced problem-solving capabilities [22]

Core Viewpoint - Boston Scientific (BSX) is expected to report fourth-quarter fiscal 2024 results on February 5, with projected adjusted earnings between 64-66 cents per share and revenue growth of approximately 16.5-18.5% on a reported basis, indicating a strong performance compared to the previous year [1][2]. Financial Projections - The Zacks Consensus Estimate for earnings is steady at 65 cents per share, reflecting an 18.2% growth from the same quarter last year [2]. - BSX's earnings have consistently beaten the Zacks Consensus Estimate in the past four quarters, with an average earnings surprise of 8.29% [3]. Earnings Expectations - Boston Scientific has an Earnings ESP of -0.60%, which suggests a lower likelihood of beating estimates this quarter [4]. - The company currently holds a Zacks Rank of 3 (Hold) [5]. Market Demand and Growth Factors - Increased hospital admissions in the U.S. have driven demand for BSX's products, with expectations of continued sales growth due to its innovative pipeline and expansion into faster-growing markets [6]. - Despite challenges in profitability due to supply chain issues and rising costs, BSX is well-positioned for decent sales results [7]. Geographic Performance - Strong growth is anticipated across all geographic regions, particularly in EMEA and Asia Pacific, with notable performance in China and Japan driven by new product launches [8][10]. - The WATCHMAN subsegment within the Cardiovascular division is expected to report strong growth, with revenues estimated at $406 million, a 17.6% increase year-over-year [13][14]. Segment Performance - The Interventional Cardiology business is projected to achieve revenues of $672 million, reflecting a 9.4% improvement [15][16]. - Peripheral Intervention revenues are estimated at $628 million, indicating a 17.8% growth [17][18]. - The Urology/Pelvic Health and Endoscopy segments are also expected to show strong growth due to innovative products [19]. Stock Performance - BSX stock has increased by 66.9% over the past year, outperforming its industry and major competitors [22]. - However, the stock is considered expensive with a forward P/E ratio of 36.54, higher than the industry average of 22.93 [25]. Analyst Insights - The Wall Street average price target for BSX is $103.74 per share, suggesting a modest upside of 1.4% from current levels [26]. - Despite macroeconomic challenges, BSX is witnessing strong demand across its core businesses, indicating potential for future growth [29].

Group 1 - Boston Scientific (BSX) closed at $102.27, with a +0.32% change from the previous day, outperforming the S&P 500's daily loss of 1.46% [1] - The stock has increased by 12.44% over the past month, leading the Medical sector's gain of 1.84% and the S&P 500's gain of 1.08% [1] Group 2 - Boston Scientific is set to release its earnings report on February 5, 2025, with an expected EPS of $0.65, reflecting an 18.18% increase from the prior-year quarter [2] - The consensus estimate anticipates revenue of $4.4 billion, indicating an 18.13% increase from the same quarter last year [2] Group 3 - Recent adjustments to analyst estimates for Boston Scientific are important, as they reflect short-term business trends and analyst optimism about the company's profitability [3] - Positive estimate revisions can lead to near-term stock movements, which investors can capitalize on using the Zacks Rank system [4] Group 4 - The Zacks Rank system ranges from 1 (Strong Buy) to 5 (Strong Sell), with 1 stocks averaging an annual return of +25% since 1988 [5] - Currently, Boston Scientific holds a Zacks Rank of 3 (Hold), with the Zacks Consensus EPS estimate having moved 0.1% lower in the past month [5] Group 5 - Boston Scientific has a Forward P/E ratio of 36.8, which is higher than the industry average Forward P/E of 19.01, indicating it is trading at a premium [6] - The company has a PEG ratio of 2.67, compared to the Medical - Products industry's average PEG ratio of 2.15 [7] Group 6 - The Medical - Products industry, part of the Medical sector, holds a Zacks Industry Rank of 93, placing it in the top 38% of over 250 industries [7] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [8]

Core Viewpoint - Belo Sun Mining Corp. has appointed Mr. Jack Lunnon as a director, nominated by La Mancha Investments, to enhance the company's technical expertise and support the advancement of the Volta Grande Project [1][5]. Company Overview - Belo Sun Mining Corp. is focused on mineral exploration and development, particularly gold properties in Brazil, with its primary asset being the 100% owned Volta Grande Gold Project located in Para State, Brazil [5]. Appointment Details - Mr. Jack Lunnon, who has over fifteen years of experience in geology, mining, and investments, will bring significant technical expertise to the board [2]. - Lunnon has served as Chief Technical Officer for La Mancha since 2021 and has prior board experience with Elemental Altus Royalties Corp. [2]. - His qualifications include being a Chartered Geologist and holding a Master of Geology degree, along with expertise in geological modeling and resource geology [3]. Professional Background - Before joining La Mancha, Lunnon worked as a Consultant Geologist for SLR Consulting, where he conducted due diligence reviews and generated NI 43-101-compliant reports [4]. - He has extensive geological exploration experience across Africa, the Middle East, and Australia, contributing to his advanced resource modeling skills [4]. Strategic Importance - The appointment of Lunnon is seen as a strategic move to leverage his global technical experience for the benefit of all stakeholders involved in the Volta Grande Project [5].